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Background: Multiple chemical sensitivity (MCS) is a condition characterized by recurrent, self-reported symptoms from
multiple organ systems, attributable to exposure to a wide range of chemically unrelated substances at low levels. The
pathophysiology is unknown, and affected individuals generally favor avoidance of the symptom triggering substances
as a coping strategy. The impact of MCS on daily life may thus be severe. An intervention that may effectively reduce
the impact of MCS, alleviate the symptoms and the psychological distress associated with the condition is therefore
highly needed. In this study we will assess the effects of a mindfulness-based cognitive (MBCT) program on MCS.
Methods/Design: Using a randomized controlled design (RCT), we will compare MBCT with treatment as usual (TAU).
The MBCT intervention will include 8 weekly 2.5 hour sessions, and 45 minutes of mindfulness home practice 6 days
each week. Participants will be asked to complete questionnaires at baseline, post-treatment, and at 6 and 12 months’
follow-up. Based on sample size estimation, 82 participants will be randomized to either the MBCT intervention or to
TAU. The primary outcome will be a measure of the impact of MCS on the participants’ lives. The secondary outcome
measures are physical symptoms of psychological distress, perceived stress, illness perceptions, QOL, and work ability.
Lastly, we will assess whether any effect of MBCT on the primary effect measure is mediated by level of mindfulness,
self-compassion, perceived stress, and rumination.
Discussion: This trial will provide important information on the effects of MBCT on MCS.
Trials registration: Clinical trials identifier NCT01240395
Keywords: Mindfulness-based cognitive therapy, Multiple chemical sensitivity, Randomized controlled trialBackground
The term ‘multiple chemical sensitivity’ (MCS) is applied
to a condition of recurrent, self-reported symptoms from
multiple organ systems. Other labels have been ascribed
to the symptoms, but MCS is widely used in the scientific
literature, and thus, will be used here without reference to
any assumptions about etiology. The symptoms follow
perceived exposure to a wide range of airborne chemicals
at levels normally considered non-toxic [1]. Frequently
reported symptom-eliciting chemicals and environmental* Correspondence: christian.riise.hauge@regionh.dk
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reproduction in any medium, provided the oragents include fragranted products, motor-vehicle exhaust
fumes, cleaning agents, freshly printed papers or maga-
zines, and smoke from wood burners [2,3]. A recent
population-based study showed that extreme fatigue,
headache, gastrointestinal symptoms, muscle and joint
pain, upper airway symptoms, and irritability are the most
frequently reported symptoms [3]. It has been documen-
ted that symptoms from the central nervous system
(CNS) other than headache are the single most predictive
factor of the severity of MCS [2]. Despite the limited num-
ber of studies investigating syndrome stability in MCS,
evidence points to MCS being a chronic condition [4,5].
The pathophysiological mechanisms behind MCS re-
main unknown [6,7]; however, current evidence suggests
that MCS is more likely to be due to individual suscepti-
bility factors than to a toxicological response to commonLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cates that sustained levels of arousal may be a risk factor
in the development of MCS [9]. Several underlying
mechanisms have been proposed, such as sensitization of
the CNS [10,11], and symptom acquirement due to clas-
sical conditioning [12,13]. Increased levels of depression,
anxiety, and somatization, are frequently reported [14-17],
and it has thus been suggested that MCS belongs to a
spectrum of somatoform disorders [18]. However, evi-
dence supporting this view is sparse.
Provocation studies examining responses of individuals
with MCS when exposed to either active or sham provo-
cation have found that, in general, these individuals can-
not differentiate between active and sham exposures,
symptomatically or otherwise. While the mechanisms by
which airborne chemicals trigger MCS symptoms are
unclarified, the significance of mental representations of
illness has been found to be particularly influential in
patients presenting with medically unexplained symptoms,
in terms of onset, persistence of symptoms, and degree of
disability [19], when comparing a medically unexplained
illness with an illness of known physiological origin [20].
Currently, there are no evidence-based treatments or
clinical guidelines for MCS [21,22]. A typical coping re-
sponse seems to be that of avoiding potential chemical
triggers, typically through the creation of a safe living
space and the application of protective routines, thus
avoiding exposure to symptom-eliciting stimuli [23,24].
However, this may come at a cost, because several aspects
of the patients’ everyday life, including lifestyle, social rela-
tions, and occupational conditions, are affected by the be-
havior [23]. Considering the impact MCS has on the lives
of those affected, an effective evidence-based treatment is
urgently needed.
Mindfulness, defined as ‘the awareness that emerges
through paying attention on purpose, in the present mo-
ment, and non-judgmentally to the unfolding of experi-
ence moment by moment’ [25], is becoming increasingly
popular, and mindfulness-based interventions show prom-
ise in the treatment of stress-related medical disorders
[26]. It has been suggested that mindfulness-based inter-
ventions could be useful in the treatment of such disor-
ders by improving disease management and reducing
psychological distress, thereby improving wellbeing [27].
A few clinical trials have assessed the effect of
mindfulness-based therapy on conditions with hypothe-
sized shared illness mechanisms and a high degree of co-
morbidity to MCS; such as fibromyalgia [28,29], irritable
bowel syndrome [30] and chronic fatigue [31]. Although
the results of these studies are inconclusive, the findings
are generally positive, warranting larger randomized clin-
ical trials (RCTs).
One study, applying a non-randomized waiting-list
design, evaluated the effect of a mindfulness-basedintervention program on participants with MCS with vari-
ous types of co-morbidity to other functional disorders
[32]. The results showed that the mindfulness-based inter-
vention was associated with a significant decrease in
symptoms of somatization and psychological distress
compared with the waiting-list control group. However,
the study did not include outcome measures directly
related to the participants’ MCS, so it is uncertain whether
the intervention had any effect on this outcome. The feasi-
bility of a MBCT program for MCS was tested in a recent
randomized pilot trial. The study concluded that a group
intervention was feasible for MCS and a larger rando-
mized trial could be considered [33].
Objectives
The main aim of the proposed study is to evaluate
whether an 8-week mindfulness-based intervention pro-
gram is associated with a reduction in the degree to which
MCS affects participants’ lives (for example, ability to
travel, to be around others and to enjoy social activities).
The secondary aims are to evaluate whether the interven-
tion is associated with a reduction in commonly experi-
enced symptoms (for example, muscle or joint aches,
headache, difficulty in concentrating), severity of reactions
to common chemicals, psychological distress (anxiety, de-
pression, and somatization), and perceived stress, and
whether the intervention increases participants’ quality of
life (QOL) and work ability. The study will also assess
whether the intervention affects the participants’ illness
perceptions. Finally, it will assess whether degree of mind-
fulness, stress, self-compassion, and rumination are pos-
sible mediators of a treatment effect.
Hypotheses
The primary hypothesis is that the degree to which MCS
affect participants’ daily lives will be significantly reduced
in the mindfulness intervention group compared with the
control group. The secondary hypotheses are 1) that we
expect a significant alleviation of MCS symptoms, symp-
toms of depression, anxiety, somatization, and perceived
level of stress, thereby improving overall psychological
wellbeing compared with that in the control group, and 2)
that the mindfulness intervention will lead to positive
changes in illness perception and will improve QOL and
work ability.
In terms of mediating treatment mechanisms, we expect
that a treatment effect will be mediated by the level of
mindfulness, as was found in a previously conducted trial
with participants with a similar level of disability [30].
Additionally, we will assess whether self-compassion,
which was recently found to mediate a reduction in de-
pressive relapse [34], also mediates a treatment effect in
our group of patients. Moreover, and in line with a previ-
ous prospective study that established prolonged stress as
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investigate whether the reverse is also true; that is,
whether a reduction in the level of stress is associated with
a reduction in the degree to which chemicals affect parti-
cipants’ daily lives. Furthermore, we will explore whether
a positive change in illness perceptions (for example, a
greater sense of control, an increased sense of understan-
ding of MCS, and a reduction in the concern associated
with MCS) will mediate a treatment effect. Lastly, recent
research suggests that rumination could be a transdiag-
nostic factor underlying several psychiatric conditions
[35], and we will investigate whether it is also a possible
mediator of a treatment effect for individuals with MCS.Methods/Design
Empirical design
The study is an RCT in which the effect of a mindfulness-
based intervention program will be compared with that of
a TAU control group. Because this is a pragmatic trial, we
will enhance the external validity by keeping exclusion cri-
teria to a minimum. The study will be undertaken in the
cities of Copenhagen and Aarhus, Denmark.
Participants
Participants will be recruited through several sources.
First, we will contact GPs in the Copenhagen and Aarhus
areas and provide them with information about the study.
Second, we will contact individuals with MCS registered
at the Danish Research Centre for Chemical Sensitivities
who have agreed to be contacted about research projects,
and invite them to participate in the study. Lastly, we will
advertise the study on the website of the Danish Research
Centre for Chemical Sensitivities, in patient magazines,
and in local newspapers.
Inclusion criteria
Participants will need to be aged 18 to 65 years, and
provide written, informed consent. They will need to ful-
fill the expanded consensus criteria for MCS [36,37], as
follows. 1) The condition has lasted for at least 6 months
causing significant lifestyle or functional impairments; 2)
there are reproducible CNS symptoms and 3) at least one
symptom from another organ system; 4) the symptoms
occur in response to low levels of exposure to 5) multiple
unrelated chemicals and 6) improve or are resolved when
these inciting substances are removed.
Exclusion criteria
The exclusion criteria are: presence of 1) a psychotic or bi-
polar disorder, 2) suicidal ideations, 3) drug or alcohol
abuse; and 4) previous engagement in a mindfulness-
based intervention program.Assessment
Before randomization, all participants will be assessed,
using the Schedules for Clinical assessment in Neuro-
psychiatry (SCAN), an instrument to assess and classify
the psychopathology and behavior associated with major
psychiatric disorders. The interview contains an extensive
section on somatic symptoms, providing an opportunity
to obtain an overview of the participants’ symptoms from
various organ systems. We will also use SCAN to assess
whether the participants fulfill the criteria for various
other functional somatic syndromes, applying the SCAN
algorithms suggested by Fink and Schröder [38]. Classifi-
cation of such syndromes will be based solely on the inter-
view rather than by a thorough medical investigation, as
the purpose is purely descriptive. Lastly, the SCAN inter-
view will be used to identify subjects who present with se-
vere psychopathology, and who thus will be excluded
from participation.
Concerning the specific needs that chemically intolerant
people may have in terms of environment, eligible partici-
pants will be asked to consider whether they are able to
engage in a group setting and to refrain from using fra-
granced products while attending the classes.
Randomization
The randomization will be carried out as follows. Once we
have recruited 16 to 20 eligible participants (the number
of participants required to start off a MBCT group) who
have signed a written consent form, they will be rando-
mized by a computer-generated allocation sequence either
to intervention with MBCT or to the TAU control condi-
tion. The randomization will be pre-programmed so as to
produce equal numbers in both groups. The random-
ization procedure will be carried out at the Research
Centre for Chemical Sensitivities by a researcher who is
otherwise not involved in the trial, thus securing conceal-
ment to the research team. Once the randomization has
been carried out, the first author will contact participants
by telephone and email to inform them about the
allocation.
Intervention
The mindfulness-based intervention in this RCT is mod-
eled on MBCT, which is a group skills-based training ap-
proach developed to prevent relapse of depressive
episodes [39]. MBCT is partly based on the mindfulness-
based stress reduction (MBSR) program developed by
Kabat-Zinn [40], and partly on cognitive therapy for de-
pression. MBCT focuses on the aspect of ‘de-centering’,
meaning not accepting the content of thoughts as facts
and not identifying with thoughts [39]. The MBCT pro-
gram has been fully manualised by Segal and colleagues,
describing the exercises and rationale in detail [41]. How-
ever, as the original program was developed to prevent
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made to the curriculum in this trial to adapt it for indivi-
duals with MCS. For example, session seven in the MBCT
program deals with identifying signs of depressive relapse,
but in our study, the emphasis will be on applying mind-
fulness in coping with stress. The main treatment compo-
nent will be mindfulness exercises, which includes various
forms of meditation and yoga. The purpose of the mind-
fulness exercises is to cultivate the ability to stay in the
present with full awareness, and to practice an attitude of
acceptance of whatever sensation, pleasant or unpleasant,
that arises in the present moment. Before commencing
the program, all the participants will be invited to an indi-
vidual session with the group therapist with the aim of
getting to know the participants and answering questions
about the program. The program will be given to groups
with a maximum of 15 participants, and will comprise
eight weekly sessions, each 2.5 hours long, plus a half-day
of silent retreat between weeks 6 and 8. Additionally, dur-
ing the program, participants will be encouraged to do
home work assignments of up to 45 minutes 6 days a
week. Guided instructions will be provided on a CD for
home practice. If a participant is unable to attend a ses-
sion, they will be e-mailed any written material handed
out during the class. Finally, participants will be offered
follow-up sessions at months 1, 3, and 6 post-treatment.
The therapists teaching mindfulness in the trial will be
two clinical psychologists, both of whom have extensive
experience in delivering mindfulness-based treatment.
They have undergone formal education in mindfulness-
based therapies from The Oxford Mindfulness Centre
and from the Umass Centre for Mindfulness in Medi-
cine, Healthcare, and Society, respectively.Treatment as usual
The control condition in this trial is a TAU control
group for comparison with the intervention group. TAU
in this trial does not refer to a specific treatment regi-
men but rather to unconstrained services that may vary
across participants. Participants randomized to the TAU
group will be informed that they should continue receiv-
ing their usual care from their GP, specialist physician or
other health professional(s) according to their needs.
Control participants will be requested not to engage in
any mindfulness program until the trial has been com-
pleted; nevertheless, as part of the post-intervention
questionnaire, control participants will be asked whether
they have initiated a mindfulness program themselves,
providing an opportunity to control for confounding in
the subsequent analyses should some have in fact done
so. The treatments that the participants will receive will
be registered for both the intervention group and con-
trol group as part of the trial.Measurements
All outcomes will be measured at baseline, post-treatment,
and at the follow-ups at 6 and 12 months.
Primary outcome
The Quick Environmental Exposure and Sensitivity
Inventory The Quick Environmental Exposure and
Sensitivity Inventory (QEESI) has been developed as a
screening instrument for MCS designed to facilitate
history-taking from individuals who report chemical in-
tolerance [42]. It consists of five scales, of which this study
will use the three: symptom severity, chemical intoler-
ances, and life impact, each containing 10 items and pro-
ducing a score ranging between 0 and 100. The Life
Impact Scale (LIS) of the QEESI, which is the primary out-
come measure, asks the participant to consider how much
their reactions have affected various aspects of their life in
terms of parameters such as diet, ability to go to work or
school, ability to be around others and enjoy social activ-
ities, and relationship with spouse and family.
A Danish translation of the QEESI has been evaluated
in terms of internal consistency, test-retest reliability, sen-
sitivity, and specificity, and in order to establish normative
data [43]. The psychometric properties of QEESI were
found to be satisfactory, which is in accordance with other
similar studies [42,44].
Secondary outcomes
Symptom-Check List-92 The Symptom Checklist (SCL-
92) is a self-administered questionnaire for measuring psy-
chological distress or the degree of affective distress. The
questionnaire covers nine dimensions; however, only the
somatization, depression, and anxiety scales will be used
in this study. The items are measured on a five-point
Likert scale. The SCL-92 has been translated into Danish,
and has been psychometrically evaluated in a Danish
population, showing that the non-psychotic scales func-
tion well and seem to reflect a single broad dimension of
stress [45].
World Health Organization Quality Of Life, Brief
Version The World Health Organization Quality of Life
(WHOQOL-BREF) is a relatively short multidimensional
questionnaire, which is a generic measure of health-
related quality of life. The questionnaire comprises the
domains of physical health, psychological wellbeing, and
social conditions and environment, as well as a general
QOL domain. The questionnaire has been shown to have
good psychometric properties and to adequately assess
domains relevant to QOL in a large number of cultures
worldwide [46].
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is designed to measure the degree to which situations in a
person’s life are appraised as stressful [47]. The PSS was
designed for use with community samples with at least a
secondary school education. The items are easy to under-
stand and the response options are simple to grasp [48].
The PSS has been adapted to a short version consisting
of 10 questions, the PSS-10, which has proven to be a
valid and reliable measure of perceived stress [48].
Brief Illness Perception Questionnaire The Brief Illness
Perception Questionnaire (Brief IPQ) has nine items and
is designed to measure patients’ cognitive and emotional
representations of their illness. Five items assess cognitive
illness representations, two items assess emotional repre-
sentations, and one item assesses illness comprehensibil-
ity. The items are rated using a response scale of 0 to 10.
Each causal item is grouped into categories (for example,
stress, lifestyle, hereditary factors), which are determined
by the particular item studied. The Brief IPQ has been
found to have good test-retest reliability and validity [49].
Role Work Functioning Index The Role Work Func-
tioning Index (RWFI) is a measure of work ability, a con-
cept that refers to the balance between the demands of a
job and the individual’s capacity to master these demands.
As opposed to most instruments that assess work ability,
the RWFI does not ask respondents to consider their
health when responding to questions about their work
ability. The index consists of seven questions tapping
into the following dimensions of work demands: tempo;
workload; and physical, social, and cognitive job demands
(K. Thielen, 2011, personal communication).
Mediators
Rumination-reflection questionnaire
The rumination subscale of the Rumination-Reflection
Questionnaire is a 12-item questionnaire measuring the
tendency to recurrently think about threats, losses, or
injustices to the self [50]. The scale has been found to tap
into a type of self-attentiveness closely linked to the per-
sonality trait of neuroticism. The authors reported an in-
ternal consistency coefficient of 0.90 for the rumination
subscale.
Self-Compassion Scale
The Self-Compassion Scale measures the ability to have a
healthy stand towards oneself that does not involve eva-
luations of self-worth [51]. Research has shown that self-
compassion is associated with wellbeing and greater psy-
chological health. The questionnaire used in this trial is a
short form consisting of 12 questions, which has been
shown to have a high level of correlation with the original
questionnaire [52].Five Facet Mindfulness Questionnaire
The Five Facet Mindfulness Questionnaire (FFMQ)
assesses five general facets of being mindful in daily life:
observing, describing, acting with awareness, non-
reactivity to inner experience, and non-judging of inner
experience. Items are rated on a five-point Likert scale
ranging from 1 (never or very rarely true) to 5 (very often
or always true). Previous studies have provided good sup-
port for construct validity of the FFMQ; furthermore, four
of the five facets (except for ‘acting with awareness’) have
been found to be significantly correlated with meditation
experience [53].
Statistical analysis
Statistical analyses will be conducted using the latest ver-
sion of SPSS. Group allocation (intervention or control)
will be concealed for the statistician who will perform the
statistical analyses. Descriptive statistics for the two groups
will be generated. In the statistical analyses of a possible ef-
fect, the mixed model repeated measures method will be
used to test the effect of the intervention and the effect of
time. Level of significance will be set at P<0.05. All effect
measures will be inspected for normality, and transformed
as appropriate. Missing values will be handled by the mul-
tiple imputation method. Data analysis will be performed
based on the intention-to-treat principle, meaning that all
participants will be included in the analysis irrespective of
their compliance with the intervention protocol. Lastly, an
additional per-protocol analysis will also be conducted.Sample size
The sample size estimation is based on the primary effect
measure, the QEESI. Results from a recently conducted
study evaluating a Danish translation of the QEESI,
showed that the patient sample had a mean value of 61.5
with a standard deviation of 24.3 on the LIS [43]. In this
study, a clinical effect will be set as a 25% reduction on
the LIS of the QEESI, which we regard as a clinically
meaningful reduction in the effect of MCS on participants’
daily lives. With a reduction of 25% on the LIS, the study
will need to include 41 experimental subjects and 41 con-
trol subjects to be able to reject the null hypothesis, that
is, that the population means of the experimental and
control groups are equal with probability (power) of 0.8.
The type I error probability associated with this test of this
null hypothesis is 0.05.
Ethical considerations
The trial has obtained approval from the regional ethics
committee (registration number H-2010-122), and is
registered with the Danish Data Protection Agency.
There is no documentation of any side effects or serious
risks related to participation in an MBCT program.
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thoughts and emotional reactions during the program,
which we expect to deal with during the group sessions. If
this is insufficient, the study therapists will be available for
individual counseling, or they may refer participants to
relevant treatment elsewhere if considered appropriate.
Any adverse events reported by the participants will be
registered and reported in future publications.
Discussion
MCS is a condition that may seriously affect many aspects
of the lives of afflicted individuals, and markedly reducing
their health-related QOL [54,55]. Hence, an intervention
that contributes to decreasing the negative effects of MCS
is urgently needed. This study protocol describes a trial
that will test MBCT as an intervention for MCS, with the
primary aim of reducing the negative effects on the
patient’s life caused by MCS. We will compare a group re-
ceiving MBCT with a control group receiving TAU. The
study participants may seek out or continue any treatment
they see fit while enrolled in the study. Participant behav-
ior in terms of seeking other treatment (for example, med-
ical or psychological) will be registered as part of the trial.
This study has several strengths. It is the first RCT
to assess the effect of a mindfulness-based interven-
tion for MCS. The results will be important in clarify-
ing whether a mindfulness-based approach is indeed
an effective method in reducing the negative effects
of MCS on patients’ lives. Furthermore, the study will
examine other effect measures that are likely to be
affected by the participants’ intolerance, such as psy-
chological distress, work ability, and QOL, and will
thus provide valuable information on the effects of
the intervention on these parameters as well. More-
over, the study will assess several potential mediating
mechanisms of a possible treatment effect, which will
be important in understanding the processes that
underlie MBCT and what aspects of the intervention
may be of particular importance for MCS.
The study also has some limitations. First, owing to
the nature of the trial and the fact that the study
comprises a TAU control condition, it is not possible
to blind either the study participants or the thera-
pists. However, the statistician conducting the ana-
lyses will be blinded to group allocation. Second,
although we will carefully assess whether the study
participants fulfill predefined criteria for MCS, these
criteria are still based on self-report and there are no
clinical tests available to verify that the participants’
symptoms are indeed due to MCS. Finally, it will not
possible to include the most severe MCS cases in this
study due to the nature of their symptoms, which
prevent them from leaving their homes for prolonged
periods.Trial status
The trial is ongoing and participants are currently being
recruited.
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